Bausch Health Companies (BHC) vs Legend Biotech (LEGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Bausch Health Companies (BHC) has outperformed Legend Biotech (LEGN) over the past year, gaining 36.3% versus a loss of 45.9%. Over five years, BHC leads with a -67.4% price change compared with -71.8% for LEGN. Bausch Health Companies is the larger company by market cap ($3.08 billion vs $2.96 billion), about 1.0 times the size, while Legend Biotech is growing revenue faster (+64.0% vs +6.7%).
On valuation, Bausch Health Companies trades at a lower forward P/E (1.9x vs 28.9x for Legend Biotech). Bausch Health Companies converts more of its revenue into profit, with a net margin of 1.5% versus -28.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | LEGN |
|---|---|---|
| Share price | $8.22 | $15.25 |
| Market cap | $3.08B | $2.96B |
| 1-day change | -3.97% | -5.28% |
| YTD return | +18.27% | -29.85% |
| 1-year return | +36.32% | -45.86% |
| 5-year return | -67.45% | -71.83% |
| Forward P/E | 1.89 | 28.89 |
| EPS (TTM) | $-2.26 | $-0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $10.27B | $1.03B |
| Revenue growth (YoY) | +6.66% | +64.04% |
| Net income (latest FY) | $157.00M | $-296.80M |
| Gross margin | — | 61.41% |
| Operating margin | 17.66% | -13.27% |
| Net margin | 1.53% | -28.85% |
| 52-week high | $9.04 | $37.50 |
| 52-week low | $4.33 | $15.15 |
| Distance from 52-week high | -9.07% | -59.33% |
| Analyst consensus | hold | buy |
| Avg. price target upside | +2.19% | +168.39% |
| Average volume | 3.16M | 2.26M |
| Shares outstanding | 374.27M | 193.97M |
| Employees | 20,300 | 3,300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BHC has outperformed LEGN by 82.2 percentage points over the past year.
- Bausch Health Companies is more profitable, keeping 1.5 cents of every revenue dollar as net income versus -28.8 cents for Legend Biotech.
- Legend Biotech grew revenue faster in its latest fiscal year (+64.04% vs +6.66%).
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About Legend Biotech
LEGN stock →Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM).
Health Care · Biotechnology: Pharmaceutical Preparations · 3,300 employees
BHC vs LEGN FAQ
Which is bigger, Bausch Health Companies or Legend Biotech?
Bausch Health Companies (BHC) is larger, with a market capitalization of $3.08B compared with $2.96B for Legend Biotech (LEGN).
Which stock has performed better over the past year, BHC or LEGN?
BHC returned +36.32% over the past 12 months, compared with -45.86% for LEGN (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and Legend Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.